ANCHOR is a phase 1/2 open label multicenter study evaluating the safety and efficacy of melflufen plus dexamethasone in combination with either daratumumab or bortezomib in patients with relapsed refractory multiple myeloma, who have undergone 1-4 prior lines of therapy. The patients were refractory to an immunomodulatory drug and/or a proteasome inhibitor. Patients included in the daratumumab arm had not received any prior anti-CD38 monoclonal antibody therapy.

The primary objective with the study was to measure overall response rates of the different combinations. A secondary objective was progression free survival. The study was conducted in several hospitals in Europe and USA.

The study was started in Q2 2018 and was terminated in February 2022, without the last 10 planned patients in the bortezomib+melflufen arm. Data from the 56 enrolled patients were sufficient to draw scientific conclusions. Final data have been presented and published in the journal Haematologica 2023.